21 January 2016

Director Dealing

RNS Number : 6095M
Verona Pharma PLC
21 January 2016
 

Verona Pharma plc

("Verona Pharma" or the "Company")

 

Director Dealing

 

 

21 January 2016, Cardiff - Verona Pharma plc (AIM: VRP) received notification that on 20 January 2016 David Ebsworth, Director of the Company, purchased 400,000 ordinary shares of 0.1 pence each of the Company ("Ordinary Shares") at a price of 2.5 pence per Ordinary Share.

Following the transaction David Ebsworth has a total interest of 4,599,774 Ordinary Shares, representing 0.46% of the total voting rights.

 

-Ends-

 

 

For further information please contact:

 

Verona Pharma plc

Tel: +44 (0) 20 3283 4200

Jan-Anders Karlsson, Chief Executive Officer

 

 

 

N+1 Singer

Tel: +44 (0)20 7496 3000

Aubrey Powell / Jen Boorer

 

 

 

FTI Consulting

Tel: +44 (0)20 3727 1000

Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins

 

 

 

Notes to Editors

 

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.

 

Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting.  The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma.

 

Verona Pharma is also building a broader portfolio of RPL554-containing products to maximise its benefit to patients and its value.  This includes the very significant markets for COPD and asthma maintenance therapy.  The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing and has received a Venture and Innovation Award from the Cystic Fibrosis Trust.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSEDFEFFMSEEF

For further information please contact:

 

Verona Pharma plc
Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)
Aubrey Powell / James White
Tel: +44 (0)20 7496 3000

 

 

FTI Consulting
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)
James Heins
Tel: +1 203-682-8251
James.Heins@icrinc.com

Stephanie Carrington
Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us